Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Arthritis Rheum. 2011 Apr;63(4):1086–1096. doi: 10.1002/art.30230

Figure 3.

Figure 3

Dose-dependent therapeutic effects of anti-dsDNA IgM in MRL/lpr mice with significant proteinuria. A. Increasing dose correlates with better protection up to a certain point (100mg). MRL/lpr mice, at 10–11 weeks of age, were divided into five groups, 9–10 mice/group. The mice were i.p. injected with anti-dsDNA IgM mAb (clone 12H5) derived from AID−/−MRL/lpr mice or PBS only, twice a week for 8 weeks, each time, at the indicated dose. B&C. Therapeutic effect of anti-dsDNA IgM in mice with significant proteinuira at start of treatment. B. Decreased levels of urine protein in mice receiving the anti-dsDNA IgM (N = 12 for all groups). C. Decreased immune complex deposition in the glomeruli of kidneys from symptomatic mice receiving the anti-dsDNA IgM compared to PBS group, as measured by C3 staining. Mann-Whitney Rank Sum Test was used to test for significance. Error bars depict standard error.